Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value Over Cerebrospinal Fluid?

Cerebrospinal fluid (CSF) measures of amyloid and tau are the first-line Alzheimer’s disease biomarkers in many clinical centers. We assessed if and when the addition of amyloid PET following CSF measurements provides added diagnostic value. Twenty patients from a cognitive clinic, who had undergone...

Descripción completa

Detalles Bibliográficos
Autores principales: Weston, Philip S.J., Paterson, Ross W., Dickson, John, Barnes, Anna, Bomanji, Jamshed B., Kayani, Irfan, Lunn, Michael P., Mummery, Catherine J., Warren, Jason D., Rossor, Martin N., Fox, Nick C., Zetterberg, Henrik, Schott, Jonathan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2016
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5181662/
https://www.ncbi.nlm.nih.gov/pubmed/27567830
http://dx.doi.org/10.3233/JAD-160302
Descripción
Sumario:Cerebrospinal fluid (CSF) measures of amyloid and tau are the first-line Alzheimer’s disease biomarkers in many clinical centers. We assessed if and when the addition of amyloid PET following CSF measurements provides added diagnostic value. Twenty patients from a cognitive clinic, who had undergone detailed assessment including CSF measures, went on to have amyloid PET. The treating neurologist’s working diagnosis, and degree of diagnostic certainty, was assessed both before and after the PET. Amyloid PET changed the diagnosis in 7/20 cases. Amyloid PET can provide added diagnostic value, particularly in young-onset, atypical dementias, where CSF results are borderline and diagnostic uncertainty remains.

Ejemplares similares